Between 15 and 25 percent of people with diabetes can develop infectious ulcer and/or gangrene, which can lead them to the amputation of a foot or a leg.
This is due to the lack of control of glucose (sugar) levels in the blood, since only one in four people with the disease has good control.
You may be interested: researchers develop nanofertilizer to improve agricultural production
To the first indication of color change in the skin, sores, loss of sensitivity in the fingers or any other area of the foot, they must immediately go to the doctor to receive attention.
When the ulcer appears, it must be treated in less than 120 days to reduce the risk of amputation, said José Fernández Montequín, professor of the National Institute of Angiology and Vascular Surgery of Cuba.
“Biotechnology therapy is a recombinant human epidermal growth factor that stimulates and accelerates granulation and progressive healing.It is injected into different parts of the lesion three times a week, until the wound closes, ”said the researcher.
He pointed out that this treatment has been used for years in Cuba and Spain, among other countries, and the only contraindication is for people with cancer.
He mentioned that the injuries have been cured by up to 26 weeks in some cases, resulting in the benefit of the patient, to avoid new injuries if he keeps his glucose in control.
In Mexico, 230 treatments were donated to the Institute of Social Security and Services of State Workers (ISSSTE) of the biotechnology that occurs in plants that are in Spain and Cuba, he said.
The treatment has been tested in 350 thousand patients from 25 countries, demonstrating that it shortens the wound healing time, reducing the recovery time and complications in diabetic foot, said Irma Ceja Martínez, a member of the College of Internal Medicine of Mexico.
While Karina Renoirte López, medical director of Grupo Pisa services, said that diabetic foot ulcer is one of the most frequent complications of diabetes.
The Nephrology specialist indicated that 70 percent of patients who have had an amputation die in the first five years after the event.
Patients with diabetes are losing sensitivity to the feet and do not realize when they have a wound caused by the rubbThey are not treated on time.
Last June, the Federal Commission for Protection against Health Risks (Cofepris) authorized the marketing of the Heberprot-P drug in Mexico, by Grupo Pisa.
